
Clinical Trial: Mycapssa® (octreotide capsules) for Neuroendocrine Tumours
The delayed-release capsules contain 20mg of octreotide. The mainstay somatostatin analogues for Neuroendocrine Tumour patients are Lanreotide and Octreotide and I have blogged or mentioned them frequently, and they are probably two of the most written words in my private patient group ....... coupled with "injection" or "shot". For years, people have talked about the need for different delivery systems including capsules and even nasal sprays. Many patients have indicated a preference for an easier route into the system with similar efficacy. I have been following a few of these initiatives in an article called "Somatostatin Analogues and delivery methods in the pipeline". While generic somatostatin analogues have helped people and organisations with cost, these generics are still using injection delivery systems. Two diseases in particular have been benefitting for some…